Thursday, December 29, 2011

Cytokinetics takes a swing at Lou Gehrig's disease

Cytokinetics Inc.’s 14-year history is marked by turns — out of cancer and into muscle programs — and a key heart failure drug partnership with biotech giant Amgen Inc. But the South San Francisco company (NASDAQ:CYTK) hasn’t yet taken a drug into the final of three phases of clinical trials, much less brought a drug to market.
Whether Cytokinetics reaches that ultimate goal could rest in the outcome of a mid-stage trials in a tough disease, amyotrophic lateral sclerosis — also known as Lou Gehrig’s disease. A strong showing would increase the chance of Cytokinetics finding a deep-pocketed partner to take the drug into Phase III trials.

No comments:

Post a Comment